Risk-stratified treatment — why two children get different plans
Medically reviewed by Dr. Naresh Gundu, Medical Oncologist, CION Cancer Clinics · Last reviewed June 2026
If another child in the ward has the same cancer as yours but is receiving a different treatment, it is not a mistake — and it is not because one child is more valued. Why child cancer treatment differs comes down to a precise, evidence-based process called risk stratification: assigning each child a risk group based on the specific biology of their cancer, so that the intensity of treatment is matched exactly to what that cancer requires. This page explains what that process looks like, in plain language.
Same cancer, different plan — why the biology inside the cancer matters as much as the diagnosis
Risk-based treatment explained — what low, standard, and high risk actually mean for your child
Treatment intensity paediatric — calibrated to protect long-term health, not just treat the cancer
Tumour board for every child — the plan is agreed by a team, not decided by one doctor
4.8 · 800+ Google reviews · 15,000+ patients treated
17+
Cancer Specialists on Panel
96.9%
Breast Cancer Survival Rate*
15,000+
Patients Treated
4.8★
Google Rating (800+ reviews)
Understanding risk-based treatment child cancer
Why two children with the same cancer can get very different plans
When a child is diagnosed with cancer, parents often talk to other families on the ward. It can be confusing — and even frightening — to discover that another child with the same cancer name is on a completely different treatment schedule. This section explains why, and why that difference is a sign that care is being done right.
Cancer is not just a name — it is a biological profile. When we say a child has leukaemia, or a brain tumour, or a kidney cancer, that name describes the organ or cell type where the cancer started. But underneath that name, two children can have cancers that look entirely different under a microscope, carry different chromosomal changes, and behave very differently in the body. One child's leukaemia cells may carry a genetic change that makes them respond very well to gentler treatment. Another child's leukaemia cells may carry a different change that makes them more likely to resist treatment unless a more intensive approach is used from the start.
Risk stratification is the process of measuring those differences. Before recommending a treatment plan, the paediatric oncology team gathers information from biopsy results, molecular tests, imaging scans, the child's age, and — often — the cancer's early response to an initial dose of therapy. All of that information is combined to place the child in a risk group. The risk group determines the intensity and duration of treatment: how many cycles are needed, whether radiation is part of the plan, and how closely the child needs to be monitored for response.
This is how modern paediatric oncology protects children from both under-treatment and over-treatment. Under-treating a high-risk cancer gives it a chance to grow back. Over-treating a low-risk cancer exposes a child to side effects — including long-term effects on growth, hormones, learning, and fertility — that were never necessary. Risk-based treatment in child cancer is specifically designed to avoid both mistakes. At CION Cancer Clinics, every child's risk group is confirmed and the treatment plan is agreed by a multi-disciplinary tumour board before a single dose of therapy begins.
Did you know?
Modern paediatric oncology protocols assign risk groups before treatment begins — and re-evaluate the group after the first treatment phase. If a cancer responds faster than expected, it may be possible to reduce treatment intensity mid-course, sparing your child from unnecessary exposure to therapy. This re-assessment approach, sometimes called response-adapted therapy, is one of the most important advances in childhood cancer care over the past two decades. It reflects a core principle of paediatric oncology: treat no more than the cancer requires.
Treatment intensity paediatric — what the team looks at
The four factors that shape your child's treatment plan
Risk stratification is not guesswork — it is a structured evaluation of four well-established factors. Each one tells the oncology team something specific about how aggressive the cancer is and how much treatment is needed. Understanding these factors helps you ask informed questions in the consultation room.
Factor 1
Stage — how far the cancer has spread
Stage tells the team whether the cancer is confined to one place, has reached nearby lymph nodes, or has spread to distant parts of the body. A localised cancer at an early stage generally needs less intensive treatment than one that has already spread. Stage is measured using imaging scans — MRI, CT, PET-CT — and sometimes a bone marrow biopsy or lumbar puncture. The stage alone does not define risk: it is one piece of a larger picture. A child with a locally advanced stage may still be classified as lower risk if the cancer's biology is favourable.
Factor 2
Biology — what the cancer cells look like and carry
Pathology and molecular testing reveal the cancer's biological identity. This includes the specific subtype confirmed by biopsy, chromosomal changes (such as certain translocations or deletions) found inside the cancer cells, and — in some cancers — the number of chromosomes in those cells. Some biological features are strongly associated with a good response to treatment. Others signal that the cancer is likely to be more resistant, requiring a more powerful approach. Molecular testing often takes one to two weeks to complete; this is normal, and it is worth waiting for because it can significantly change the treatment recommendation.
Factor 3
Age at diagnosis — biology changes with age in some cancers
In certain childhood cancers — particularly leukaemia and some brain tumours — the child's age at the time of diagnosis is an independent predictor of how the disease is likely to behave. This is not about the child being "too young" or "too old" for treatment; it is about well-established biological differences in how cancer cells behave at different developmental stages. Age is therefore built into the risk-group calculation for these cancers. The oncology team will explain whether age is a relevant factor for your child's specific diagnosis and what it means for the treatment plan.
Factor 4
Early response — how quickly the cancer reacts to initial therapy
Many risk-stratified treatment protocols include an early response assessment — a check at a defined point during the first phase of treatment to measure how much of the cancer has already disappeared. In leukaemia, this is often done by examining the bone marrow after the first few weeks of therapy. In solid tumours, imaging scans are used to measure tumour shrinkage. A rapid and deep response is a strong positive signal: it confirms that the cancer is sensitive to the current treatment and may allow the team to de-escalate intensity. A slow or incomplete response signals the need for a more aggressive approach before the cancer has the chance to become fully resistant.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
Don't see your city? Call
18002028726
— we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Your child deserves a plan built for their cancer, not a generic protocol
At CION Cancer Clinics, every paediatric case is reviewed by a multi-disciplinary tumour board. We walk this journey with you — one step at a time, with full transparency about what we know and why.
How risk based treatment child cancer works — step by step
How risk-stratified treatment works in practice — from diagnosis to plan
The journey from cancer diagnosis to the first day of treatment is not a wait — it is a carefully sequenced process of information-gathering that allows the oncology team to build the most accurate treatment plan possible. Here is what that process looks like.
1
Diagnosis confirmed — the cancer's identity is established
The first step is confirming exactly what the cancer is. A biopsy — removing a small sample of the tumour or bone marrow — is sent to the pathology laboratory where specialists examine the cells under the microscope. The result tells the team which type of cancer it is, what subtype, and how the cells look. This step is the foundation for everything that follows. At CION Cancer Clinics, pathology reports are reviewed by our own specialist team, and a second independent review can be arranged if there is any uncertainty about the diagnosis. We do not start treatment on a diagnosis we are not certain about.
2
Staging investigations — how far has the cancer spread?
Once the diagnosis is confirmed, imaging investigations measure the extent of the disease. For most solid tumours, PET-CT is the most comprehensive staging tool — it identifies the primary tumour and reveals any spread to lymph nodes or distant organs in a single scan. MRI and CT are used for detailed local assessment. For leukaemia and lymphoma, a bone marrow biopsy and sometimes a lumbar puncture (spinal tap) check for disease in the marrow and central nervous system. Together, these results give the team a complete map of where the cancer is and where it is not. This is the stage, and it is one of the most important inputs into risk group assignment.
3
Molecular testing — reading the cancer's genetic signature
Modern paediatric oncology does not stop at the microscope. Molecular tests examine the DNA and chromosomes inside the cancer cells, looking for specific changes that affect how the cancer behaves. Some chromosomal changes are associated with a cancer that responds readily to standard treatment. Others signal resistance, or a tendency to relapse, requiring more aggressive management. Molecular testing typically takes one to two weeks to complete. Waiting for these results is not a delay — it is an investment in accuracy. A treatment plan built without molecular information is less precise than one that includes it, and precision matters enormously when the patient is a child whose developing body must be protected from unnecessary harm.
4
Tumour board review — the plan is agreed collectively
Before any treatment begins, the oncology team presents the full case — diagnosis, stage, age, molecular results — to a multi-disciplinary tumour board. At CION Cancer Clinics, this board includes medical oncologists, surgical oncologists, radiation oncologists, radiologists, and pathologists. Each specialist reviews the same evidence and contributes their expertise. The group collectively agrees on the risk group classification and the treatment approach. This step exists because no single specialist can hold all the relevant expertise alone. You deserve a plan that reflects the combined knowledge of a team, not one doctor's judgment.
5
Response-adapted adjustment — the plan evolves as more is learned
Risk-stratified treatment does not end with the initial plan. After the first phase of therapy, the team re-assesses how the cancer is responding. Imaging, bone marrow tests, or blood markers are used to measure how much of the cancer remains. If the response is faster and deeper than the risk group predicted, the oncology team may reduce treatment intensity — protecting your child from cumulative side effects while still controlling the disease. If the response is slower, the plan is escalated. This ongoing adjustment — response-adapted therapy — is one of the most important advances in paediatric oncology, and it is built into the treatment protocols used at CION Cancer Clinics.
Risk group comparison — treatment intensity paediatric
Risk groups at a glance — what each one means for your child's treatment
This table summarises the general features of each risk group and what parents can typically expect in terms of treatment approach. Specific protocols vary by cancer type — your child's oncologist will explain exactly what applies to your situation during a 45-minute consultation.
Risk Group
Typical Features
What This Usually Means for Treatment
How the Group Can Change
Low Risk
Localised cancer; favourable biological features on molecular testing; younger age in cancers where age is a positive factor
Shorter overall treatment duration; fewer cycles of therapy; reduced doses where safety allows; monitoring for response at set intervals
If early response is excellent, treatment may be de-escalated further. If response is slower than expected at re-assessment, the group may be upgraded to standard risk
Standard Risk
Intermediate stage; biology neither clearly favourable nor clearly adverse; age within the typical range for the diagnosis
Standard protocol length and dosing as established by paediatric oncology research groups; close monitoring of response; regular imaging or blood-marker assessments
Good early response can lead to de-escalation in some protocols; poor early response may upgrade the child to high risk and prompt a more intensive approach
High Risk
Widespread disease at diagnosis; adverse molecular or chromosomal features; slower or incomplete early response; older age in cancers where age is an adverse factor
More intensive treatment phases; longer overall duration; additional treatment modalities may be considered; closer side-effect monitoring and supportive care planning from the start
An unexpectedly strong early response may allow some de-escalation in later treatment phases. Risk group is always re-evaluated at defined checkpoints throughout therapy
* Risk group definitions and the specific features used to assign them vary by cancer type and the treatment protocol in use. The above is a general framework. Your child's oncology team will explain the exact criteria applied to your child's diagnosis at CION Cancer Clinics.
Did you know?
Childhood cancers are generally more biologically sensitive to treatment than adult cancers of the same organ, because the rapidly dividing cells in a growing child's body respond differently to chemotherapy and radiation than mature adult tissue. This is one of the key reasons that risk-stratified paediatric oncology protocols have been able to progressively reduce treatment intensity for low-risk patients over decades of clinical research — improving quality of life for long-term survivors without compromising disease control.
You deserve an honest answer, not a rushed one
We walk this journey with you — 45 minutes at a time
Every consultation at CION Cancer Clinics is 45 minutes. No rushing. No unnecessary tests. Transparent costs. A tumour board for every child — because your child deserves decisions made by a team, not a single opinion.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Successful Chemotherapy & Radiation Done by Dr. Owais Mohammed & Dr. Kirti Ranjan
Watch video →
Successful Chemotherapy Done by Dr. C Raghavendra Reddy
Watch video →
Surgery, Chemo & Radiation Done by Dr. Imaduddin, Dr. Vinay, Dr. Owais, Dr. Kirti
Watch video →
Successful Radical Thymectomy Done by Dr. Mohammed Imaduddin & Dr. Vinay Mamidala
Watch video →
Successful Surgery Done by Dr. Rajender Byshetty
Watch video →
Successful Chemo & Surgery Done by Dr. Imad, Dr. Vinay, Dr. Owais & Dr. Raghavendra
Watch video →
Successful Chemo & Surgery Done by Dr. Imad, Dr. Vinay, Dr. Owais & Dr. Raghavendra
Watch video →
Successful Chemo & Radiation Done by Dr. Owais Mohammed & Dr. Kirti Ranjan Mohanty
Watch video →
Successful Breast Cancer Surgery Done by Dr. Imaduddin Mohammed & Dr. Vinay Mamidala
Watch video →
Successful Chemotherapy Done by Dr. Bharati Devi Gorantla
Watch video →
Successful Chemo & Surgery Done by Dr. Owais Mohammed & Dr. Imaduddin Mohammed
Watch video →
Successful Chemotherapy Done by Dr. Gundu Naresh
Watch video →
Successful Bone Marrow Transplantation - Neuroblastoma
Watch video →
Successful Surgery & Chemo - Carcinoma of Caecum
Watch video →
Successful Oral chemotherapy & mastectomy surgery
Watch video →
Successful Oral chemotherapy & mastectomy surgery
Watch video →
Successful Chemotherapy
Watch video →
Successful Surgery by Dr. Mohammed Imaduddin
Watch video →
Successful Bone Marrow Transplantation
Watch video →
Successful Oral chemotherapy & mastectomy surgery
Watch video →
Successful Oral chemotherapy & mastectomy surgery
Watch video →
Successful Chemotherapy
Watch video →
Successful Buccal Mucosa Surgery
Watch video →
Successful Complex Surgery Mandibulectomy Reconstruction
Your questions about why children with the same cancer get different treatment plans — answered
Why does my child's oncologist suggest a different treatment from another family's child with the same cancer?
Even when two children are diagnosed with the same type of cancer, the details inside that cancer — the biology, the stage, the child's age, and how early the cancer was caught — can differ considerably. Risk stratification means the treatment team places each child into a risk group based on those specific details. A child in a low-risk group may need a shorter, less intensive course of treatment, while a child in a high-risk group needs a more powerful approach. This is intentional and evidence-based. It means your child is not being under-treated or over-treated — they are receiving the intensity of treatment that their own cancer, in their own body, actually requires.
What does "risk group" mean in childhood cancer treatment?
A risk group is a classification — usually low risk, standard risk, or high risk — that tells the treatment team how aggressive the cancer is likely to be and how much treatment is needed to control it. Risk groups are assigned after all the diagnostic information is gathered: the stage of the disease, the child's age, the specific subtype confirmed by biopsy and molecular testing, and often the results of a short trial of initial therapy. The risk group is not a prediction that your child will or will not recover — it is a framework that helps the oncology team calibrate treatment to be as effective as possible while protecting your child from unnecessary side effects.
What factors go into deciding how intensively my child will be treated?
Several factors are weighed together. These include: (1) the stage — how far the cancer has spread; (2) the child's age at diagnosis, because biology varies with age in some cancers; (3) the specific biological subtype of the cancer, identified by pathology and molecular tests; (4) the presence or absence of certain chromosomal or genetic changes that affect how the cancer behaves; and (5) how quickly and completely the cancer responds to the earliest phase of treatment — sometimes called early response assessment. Together these factors are combined into a risk classification that guides the type, length, and intensity of treatment.
If my child is classified as high risk, does that mean the treatment is more dangerous?
More intensive treatment does carry a higher chance of side effects, and the oncology team will explain this honestly. However, high-risk treatment is recommended precisely because it offers a better chance of controlling a more aggressive cancer. At CION Cancer Clinics, every child's case is reviewed by a tumour board — a team of medical, surgical, and radiation oncologists — who discuss not just effectiveness but also how to protect your child's long-term health, growth, and development throughout treatment. Side effect monitoring is built into the treatment plan. You deserve full information about both the benefits and the expected effects of the proposed treatment before you agree to anything.
Can the risk group change during treatment?
Yes — and this is one of the important features of modern risk-stratified treatment. After the first phase of therapy, the oncology team re-evaluates how well the cancer has responded. If the cancer has responded better than expected, it may be possible to de-escalate treatment — continuing with a less intensive approach. If the response is slower or incomplete, treatment may need to be intensified. This process of re-assessment and adjustment is called response-adapted therapy, and it is designed to protect your child from both too much and too little treatment as more information becomes available.
Will my child's treatment plan be discussed by more than one doctor?
Yes. At CION Cancer Clinics, every paediatric cancer case is reviewed by a multi-disciplinary tumour board before treatment begins. This is a group of specialists — including medical oncologists, surgical oncologists, radiation oncologists, radiologists, and pathologists — who collectively review all the diagnostic results and agree on the most appropriate treatment plan. No single doctor decides alone. This process means your child benefits from combined expertise across multiple specialties, and it reflects our commitment: care led by a team, not a single opinion.
The information on this page is intended to help parents understand the principles of risk-stratified treatment in childhood cancer. It does not constitute medical advice, and it does not replace a consultation with a qualified paediatric oncologist. Every child's situation is unique — please speak with your oncology team before making any decisions about treatment.
Pediatric Cancer A–Z
Explore All Pediatric Cancer Topics
Browse our complete library of parent-facing guides, grouped by topic — from warning signs and cancer types to diagnosis, treatment, side-effect care, survivorship and family support.
